SCHEMBL1970786

SCHEMBL1970786

CCOC(=O)N[C@H]1CCN(C(=O)OCc2ccccc2)C1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.64
KMT2A Q03164 2/20 0.62
MEN1 O00255 1/20 0.62
CTSL P07711 1/20 0.58
CTSB P07858 1/20 0.58
CTSK P43235 1/20 0.58
SMN1; SMN2 Q16637 3/20 0.55
NPC1 O15118 2/20 0.55
RAB9A P51151 2/20 0.55
CYP2C19 P33261 1/20 0.53
ALDH1A1 P00352 1/20 0.51
GAA P10253 1/20 0.51
HTT P42858 1/20 0.51
F13A1 P00488 2/20 0.51
TGM2 P21980 2/20 0.51
TGM1 P22735 2/20 0.51
DPP4 P27487 2/20 0.50
KCNH2 Q12809 2/20 0.50
DPP7 Q9UHL4 2/20 0.50
KDM4E B2RXH2 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1970789 1.00 HSD11B1 (0.64) HSD11B1KMT2AMEN1CTSLCTSB
SCHEMBL13243427 0.96 HSD11B1 (0.69) HSD11B1KMT2AMEN1CTSLCTSB
SCHEMBL13161203 0.93 HSD11B1 (0.72) HSD11B1KMT2AMEN1CTSLCTSB
SCHEMBL1191110 0.91 HSD11B1 (0.64) HSD11B1KMT2AMEN1CTSLCTSB
SCHEMBL951534 0.89 HSD11B1 (0.60) HSD11B1KMT2AMEN1CTSLCTSB
SCHEMBL28519304 0.88 HSD11B1 (0.70) HSD11B1KMT2AMEN1CTSLCTSB
SCHEMBL28519302 0.88 HSD11B1 (0.70) HSD11B1KMT2AMEN1CTSLCTSB
SCHEMBL951786 0.87 HSD11B1 (0.63) HSD11B1KMT2AMEN1CTSLCTSB
SCHEMBL953899 0.86 HSD11B1 (0.59) HSD11B1KMT2AMEN1CTSLCTSB
SCHEMBL1971844 0.86 HSD11B1 (0.59) HSD11B1KMT2AMEN1CTSLCTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110166121-A1 FUSED HETEROCYCLIC COMPOUND LG LIFE SCIENCES LTD. (KR) 2011-07-07 US disclosed
US-20110166121-A1 FUSED HETEROCYCLIC COMPOUND LG LIFE SCIENCES LTD. (KR) 2011-07-07 US disclosed
US-20110166121-A1 FUSED HETEROCYCLIC COMPOUND LG LIFE SCIENCES LTD. (KR) 2011-07-07 US disclosed
EP-2334689-A2 FUSED HETEROCYCLIC COMPOUND LG Life Sciences Ltd. (KR) 2011-06-22 EP disclosed
WO-2010027236-A2 FUSED HETEROCYCLIC COMPOUND LG LIFE SCIENCES LTD. (KR) 2010-03-11 WO disclosed
WO-2010027236-A2 FUSED HETEROCYCLIC COMPOUND LG LIFE SCIENCES LTD. (KR) 2010-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166121-A1 FUSED HETEROCYCLIC COMPOUND F2, PF4, F11 HSD11B1 1232/4885KMT2A 4236/4885MEN1 849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.